Lenvatinibを投与した治療抵抗性再発甲状腺未分化癌の1例

小野田 尚佳; 徳本 真央; 野田 諭; 大平 豪; 柏木 伸一郎; 平川 弘聖

doi:10.3919/jjsa.77.291

Case Reports

A Case of Recurrent Anaplastic Thyroid Cancer Treated by Lenvatinib after Successful Long-term Multimodal Therapy

Naoyoshi ONODA, Mao TOKUMOTO, Satoru NODA, Go OHIRA, Shinichiro KASHIWAGI, Kosei HIRAKAWA

Author information

Keywords: anaplastic thyroid cancer, Lenvatinib, rupture of carotid artery

JOURNAL FREE ACCESS

2016 Volume 77 Issue 2 Pages 291-295

DOI https://doi.org/10.3919/jjsa.77.291

Details

Abstract

Anaplastic thyroid cancer (ATC) is an extremely aggressive malignancy with dismal prognosis due to resistance to multimodal therapy. Here, we present a case of ATC treated by lenvatinib, a multikinase inhibitor. A 66-year-old Japanese woman was referred to our hospital for the treatment of recurrent ATC on her neck after chemotherapy, surgery, and radio-therapy. The tumor successfully shrank within a month after initiating treatment with lenvatinib. Treatment was interrupted twice for grade 3 hypertension and proteinuria. A rupture of the carotid artery was successfully treated by emergent surgery (ligation of the carotid artery) followed by stent insertion into the subclavian artery.

Corresponding author

Register with J-STAGE for free!